The combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma (HGSC) ovarian tumor cells, according to preclinical findings published in <em>Precision Oncology.</em>
Jason Harris
Articles by Jason Harris
Lorlatinib has been granted a breakthrough therapy designation by the FDA for use in patients with <em>ALK</em>-positive metastatic non-small cell lung cancer who have previously received 1 or more ALK inhibitors.
Osimertinib has been granted a full approval by the European Union for the treatment of patients with locally advanced or metastatic <em>EGFR T790M </em>mutation-positive non–small cell lung cancer, regardless of prior treatment with an EGFR TKI.
The presence of androgen receptor splice variant-7 mRNA in circulating tumor cells was associated with poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies.
Survivors of Ewing sarcoma are left with few long-term complications, according to results from a nonrandomized observational cohort study.
Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD) extended progression-free survival in patients with multiple myeloma when used in conjunction with stem cell transplantation compared with RVD alone
Patients with chronic lymphocytic leukemia (CLL) who stopped treatment with ibrutinib due to toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation, according to the results of a recently published study.
John A. Snowden, MD, discusses guidelines that offer recommendations for screening and management of myeloma.
According to results from a randomized, double-blind, phase III study, patients with stage III or IV melanoma assigned to 10 mg/kg ipilimumab lived longer than patients assigned to a lower dose of the anti-CTLA-4 anticlonal antibody, but at the cost of greater toxicity.
The US Preventive Services Task Force (USPSTF) may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.
The PD-1 inhibitor nivolumab showed single-agent activity in previously treated patients with squamous cell carcinoma of the anal canal, resulting in an overall response rate of 24.3%.
The European Union has approved the combination of dabrafenib and trametinib for patients with <em>BRAF</em> V600-positive advanced or metastatic non-small cell lung cancer.